Skip to main content

Table 2 Baseline discontinuation rates for patients on donepezil and memantine

From: Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

 

Months 0-3

Months 0-6

Months 6-12

Annual Risk After 12 Months

Donepezil

5.1%

5.1%

10.2%

10.3%

Memantine

3.1%

3.1%

6.3%

6.3%